Overview

STAR Cape+BKM120 MBC With Brain Met

Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer. Like capecitabine, BMK120 is also effective in crossing the blood brain barrier making it a preferred candidate for its evaluation in patients with metastatic breast cancer (MBC).
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborator:
Novartis Pharmaceuticals
Treatments:
Capecitabine
Trastuzumab